2023 Q4 Form 10-Q Financial Statement

#000095017023060303 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $18.75M $20.01M
YoY Change -8.72% 7.13%
Cost Of Revenue $2.776M $2.677M
YoY Change -24.26% -8.57%
Gross Profit $15.98M $17.33M
YoY Change -5.35% 10.05%
Gross Profit Margin 85.2% 86.62%
Selling, General & Admin $23.66M $26.50M
YoY Change -17.56% -15.97%
% of Gross Profit 148.09% 152.92%
Research & Development $3.427M $4.239M
YoY Change -34.51% -29.97%
% of Gross Profit 21.45% 24.46%
Depreciation & Amortization $159.0K $200.0K
YoY Change 3.92% 0.0%
% of Gross Profit 1.0% 1.15%
Operating Expenses $27.09M $30.74M
YoY Change -20.18% -18.22%
Operating Profit -$11.11M -$13.41M
YoY Change -34.85% -38.61%
Interest Expense -$1.351M $1.432M
YoY Change 10.47% 26.61%
% of Operating Profit
Other Income/Expense, Net $1.780M $1.886M
YoY Change 29.08% 146.21%
Pretax Income -$10.68M -$12.96M
YoY Change -36.79% -41.66%
Income Tax $10.00K $78.00K
% Of Pretax Income
Net Earnings -$10.69M -$13.04M
YoY Change -36.77% -41.36%
Net Earnings / Revenue -57.02% -65.15%
Basic Earnings Per Share -$0.27
Diluted Earnings Per Share -$0.22 -$0.27
COMMON SHARES
Basic Shares Outstanding 48.75M 48.65M
Diluted Shares Outstanding 48.67M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $138.1M $144.5M
YoY Change -25.34% -27.68%
Cash & Equivalents $138.1M $144.5M
Short-Term Investments
Other Short-Term Assets $2.604M $2.900M
YoY Change -23.75% -34.26%
Inventory $7.849M $9.240M
Prepaid Expenses
Receivables $14.29M $16.92M
Other Receivables $0.00 $0.00
Total Short-Term Assets $162.9M $173.6M
YoY Change -22.32% -21.94%
LONG-TERM ASSETS
Property, Plant & Equipment $3.098M $1.556M
YoY Change 97.2% -0.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $682.0K $655.0K
YoY Change 223.22% 224.26%
Total Long-Term Assets $3.780M $3.082M
YoY Change 11.31% 6.61%
TOTAL ASSETS
Total Short-Term Assets $162.9M $173.6M
Total Long-Term Assets $3.780M $3.082M
Total Assets $166.7M $176.6M
YoY Change -21.79% -21.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.731M $3.535M
YoY Change -35.6% 9.14%
Accrued Expenses $8.302M $2.550M
YoY Change 56.43% -41.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.219M $0.00
YoY Change
Total Short-Term Liabilities $12.25M $14.33M
YoY Change -31.23% -17.57%
LONG-TERM LIABILITIES
Long-Term Debt $31.71M $33.77M
YoY Change -4.82% 1.83%
Other Long-Term Liabilities $2.476M $1.476M
YoY Change 32.62% -15.71%
Total Long-Term Liabilities $34.18M $35.24M
YoY Change -2.83% 0.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.25M $14.33M
Total Long-Term Liabilities $34.18M $35.24M
Total Liabilities $46.44M $49.57M
YoY Change -12.38% -5.21%
SHAREHOLDERS EQUITY
Retained Earnings -$294.8M -$284.1M
YoY Change 23.24% 27.8%
Common Stock $415.0M $411.2M
YoY Change 3.93% 4.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $120.2M $127.1M
YoY Change
Total Liabilities & Shareholders Equity $166.7M $176.6M
YoY Change -21.79% -21.57%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$10.69M -$13.04M
YoY Change -36.77% -41.36%
Depreciation, Depletion And Amortization $159.0K $200.0K
YoY Change 3.92% 0.0%
Cash From Operating Activities -$6.484M -$9.830M
YoY Change -58.17% -51.32%
INVESTING ACTIVITIES
Capital Expenditures $264.0K $310.0K
YoY Change 104.65% -213.97%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$264.0K -$310.0K
YoY Change 104.65% 13.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 376.0K 120.0K
YoY Change -53.69% -35.48%
NET CHANGE
Cash From Operating Activities -6.484M -9.830M
Cash From Investing Activities -264.0K -310.0K
Cash From Financing Activities 376.0K 120.0K
Net Change In Cash -6.372M -10.02M
YoY Change -57.0% -50.59%
FREE CASH FLOW
Cash From Operating Activities -$6.484M -$9.830M
Capital Expenditures $264.0K $310.0K
Free Cash Flow -$6.748M -$10.14M
YoY Change -56.83% -49.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001531177
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
sght Taxes Paid On The Net Share Settlement Of Restricted Stock Units
TaxesPaidOnTheNetShareSettlementOfRestrictedStockUnits
0
dei Document Type
DocumentType
10-Q
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2688000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5501000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7352000
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40587
dei Entity Registrant Name
EntityRegistrantName
SIGHT SCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
80-0625749
dei Entity Address Address Line1
EntityAddressAddressLine1
4040 Campbell Ave
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Menlo Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94025
dei City Area Code
CityAreaCode
877
dei Local Phone Number
LocalPhoneNumber
266-1144
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
SGHT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48749876
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
144501000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
185000000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1405000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1024000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16919000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15148000
CY2023Q3 us-gaap Inventory Net
InventoryNet
9240000
CY2022Q4 us-gaap Inventory Net
InventoryNet
6114000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2899000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3415000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
173559000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
209677000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1556000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1571000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
871000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1614000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
655000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
211000
CY2023Q3 us-gaap Assets
Assets
176641000
CY2022Q4 us-gaap Assets
Assets
213073000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3535000
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5295000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
7777000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14331000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17817000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
33765000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
33313000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1476000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1867000
CY2023Q3 us-gaap Liabilities
Liabilities
49572000
CY2022Q4 us-gaap Liabilities
Liabilities
52997000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48722219
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48722219
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48298138
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48298138
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
49000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
48000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
411119000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
399271000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-284099000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-239243000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
127069000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
160076000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
176641000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
213073000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20009000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18677000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62305000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
50788000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2677000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2928000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9105000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8696000
CY2023Q3 us-gaap Gross Profit
GrossProfit
17332000
CY2022Q3 us-gaap Gross Profit
GrossProfit
15749000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48671049
us-gaap Gross Profit
GrossProfit
53200000
us-gaap Gross Profit
GrossProfit
42092000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4239000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6053000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14129000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17626000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26504000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31541000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
85235000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
91367000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
30743000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
37594000
us-gaap Operating Expenses
OperatingExpenses
99364000
us-gaap Operating Expenses
OperatingExpenses
108993000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13411000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21845000
us-gaap Operating Income Loss
OperatingIncomeLoss
-46164000
us-gaap Operating Income Loss
OperatingIncomeLoss
-66901000
CY2023Q3 us-gaap Interest Expense
InterestExpense
1432000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1131000
us-gaap Interest Expense
InterestExpense
4057000
us-gaap Interest Expense
InterestExpense
3243000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1886000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
766000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5465000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
846000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12957000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22210000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44756000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-69298000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
78000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
37000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13035000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-22229000
us-gaap Net Income Loss
NetIncomeLoss
-44856000
us-gaap Net Income Loss
NetIncomeLoss
-69335000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.45
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48671049
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47910541
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47910541
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48538517
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48538517
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47728845
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47728845
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
136131000
CY2023Q3 sght Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
117000
CY2023Q3 sght Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
0
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3856000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13035000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
127069000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
160076000
sght Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
288000
sght Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
1000
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-222000
us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
661000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11121000
us-gaap Net Income Loss
NetIncomeLoss
-44856000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
127069000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
191759000
CY2022Q3 sght Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
186000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3223000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-22229000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
172939000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
232107000
sght Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
438000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
9729000
us-gaap Net Income Loss
NetIncomeLoss
-69335000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
172939000
us-gaap Profit Loss
ProfitLoss
-44856000
us-gaap Profit Loss
ProfitLoss
-69335000
us-gaap Depreciation
Depreciation
455000
us-gaap Depreciation
Depreciation
557000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
452000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
502000
us-gaap Share Based Compensation
ShareBasedCompensation
11121000
us-gaap Share Based Compensation
ShareBasedCompensation
9729000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
416000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
395000
us-gaap Inventory Write Down
InventoryWriteDown
219000
us-gaap Inventory Write Down
InventoryWriteDown
124000
sght Noncash Operating Lease Cost
NoncashOperatingLeaseCost
743000
sght Noncash Operating Lease Cost
NoncashOperatingLeaseCost
374000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-66000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-55000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2187000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4280000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3345000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2169000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-517000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
245000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
444000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
841000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-77000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1851000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2006000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3089000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1631000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
242000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
270000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40700000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60463000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
527000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
841000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-527000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-841000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
289000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
436000
sght Taxes Paid On The Net Share Settlement Of Restricted Stock Units
TaxesPaidOnTheNetShareSettlementOfRestrictedStockUnits
-222000
us-gaap Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
661000
us-gaap Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
728000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
436000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-40499000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-60868000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
185000000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
260687000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
144501000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
199819000
us-gaap Interest Paid Net
InterestPaidNet
3167000
us-gaap Interest Paid Net
InterestPaidNet
2350000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
81000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
46000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1. Company and Nature of Business</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sight Sciences, Inc. (the “Company”) was incorporated in the State of Delaware in 2010 and is headquartered in Menlo Park, California. The Company is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's product portfolio aligns with its two reportable operating segments: Surgical Glaucoma and Dry Eye. The products for the Surgical Glaucoma segment include the OMNI® Surgical System ("OMNI"), which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, the world's leading cause of irreversible blindness, and the SION™ Surgical Instrument ("SION"), a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare® System ("TearCare") for ophthalmologists and optometrists. TearCare is a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD) when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease.</span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, the Company has incurred losses and negative cash flows from operations. As of September 30, 2023, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">284.1</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and recorded a net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44.9</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the nine months then ended and expects to incur additional losses in the future. If the Company’s revenue levels from its products are not sufficient or if the Company is unable to secure additional funding when desired, the Company may need to delay the development of its products, scale back its business and operations, or change its business strategy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company believes that its existing sources of liquidity will satisfy its working capital and capital requirements for at least 12 months from the issuance of its financial statements. Any failure to generate increased revenue, achieve improved gross margins, or control operating costs could require the Company to raise additional capital through equity or debt financing. Such additional financing may not be available on acceptable terms, or at all, and could require the Company to modify, delay, or abandon some of its planned future expansion or expenditures or reduce some of its ongoing operating costs, which could harm its business, operating results, financial condition, and ability to achieve its intended business objectives.</span></p>
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-284100000
us-gaap Net Income Loss
NetIncomeLoss
-44900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company's unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The most significant areas requiring the use of management estimates and assumptions relate to the provision for credit losses, inventory excess and obsolescence, the selection of useful lives of property and equipment, determination of the fair value of stock option grants, and provisions for income taxes and contingencies. Management evaluates its estimates and assumptions on an ongoing basis using historical experience, existing and known circumstances, authoritative accounting pronouncements, and other factors that management believes to be reasonable, including the current macroeconomic environment, and makes adjustments when facts and circumstances dictate. Although the full impact of these factors is unknown and cannot be reasonably estimated, the Company believes it has made appropriate accounting estimates and assumptions based on information available as of the date of the unaudited condensed consolidated financial statements. Actual results could differ from these estimates and such differences could be material to the Company’s financial position and results of operations.</span></p>
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3023000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3005000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1467000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1434000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1556000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1571000
CY2023Q3 us-gaap Depreciation
Depreciation
200000
CY2022Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
500000
us-gaap Depreciation
Depreciation
600000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2550000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5307000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
910000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1033000
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
376000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
348000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1459000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1087000
CY2023Q3 sght Accounts Payable And Other Accrued Liabilitie Current
AccountsPayableAndOtherAccruedLiabilitieCurrent
5295000
CY2022Q4 sght Accounts Payable And Other Accrued Liabilitie Current
AccountsPayableAndOtherAccruedLiabilitieCurrent
7775000
CY2023Q3 sght Interest Payable Non Current
InterestPayableNonCurrent
1437000
CY2022Q4 sght Interest Payable Non Current
InterestPayableNonCurrent
1194000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
635000
CY2023Q3 sght Other Non Current Liabilities
OtherNonCurrentLiabilities
39000
CY2022Q4 sght Other Non Current Liabilities
OtherNonCurrentLiabilities
38000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1476000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1867000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
35000000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
35000000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1235000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1687000
CY2023Q3 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
33765000
CY2022Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
33313000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
33765000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
33313000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2917000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
32083000
CY2023Q3 sght Long Term Debt Maturity After Year Three
LongTermDebtMaturityAfterYearThree
0
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
35000000
us-gaap Operating Lease Expense
OperatingLeaseExpense
900000
us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2023Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P0Y9M18D
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
288000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
168000
us-gaap Operating Lease Expense
OperatingLeaseExpense
869000
us-gaap Operating Lease Expense
OperatingLeaseExpense
514000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
295000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
168000
us-gaap Operating Lease Payments
OperatingLeasePayments
885000
us-gaap Operating Lease Payments
OperatingLeasePayments
509000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
299000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
662000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
961000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
51000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
910000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
910000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
us-gaap Dividends Common Stock
DividendsCommonStock
0
sght Common Stock Vote For Each Share
CommonStockVoteForEachShare
1
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15632099
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13159736
us-gaap Sale Of Stock Description Of Transaction
SaleOfStockDescriptionOfTransaction
annual increases under the evergreen provision are equal to the lesser of (i) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Board, subject to certain limitations.
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4819906
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.67
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
19463000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
755499
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
704631
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.45
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
165384
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.68
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4705390
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.57
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2810000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2671146
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2627000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
4705390
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.57
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
2810000
CY2023Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
2100000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
6600000
CY2022Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
2400000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
7500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.58
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1200000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
17000000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47910541
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47910541
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48538517
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48538517
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47728845
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47728845
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7982
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0404
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
400
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3856000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3223000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11121000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9729000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13035000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-22229000
us-gaap Net Income Loss
NetIncomeLoss
-44856000
us-gaap Net Income Loss
NetIncomeLoss
-69335000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48671049
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48671049
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.45
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6559047
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5728939
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20009000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18677000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62305000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
50788000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2677000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2928000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9105000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8696000
CY2023Q3 us-gaap Gross Profit
GrossProfit
17332000
CY2022Q3 us-gaap Gross Profit
GrossProfit
15749000
us-gaap Gross Profit
GrossProfit
53200000
us-gaap Gross Profit
GrossProfit
42092000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
30743000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
37594000
us-gaap Operating Expenses
OperatingExpenses
99364000
us-gaap Operating Expenses
OperatingExpenses
108993000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13411000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21845000
us-gaap Operating Income Loss
OperatingIncomeLoss
-46164000
us-gaap Operating Income Loss
OperatingIncomeLoss
-66901000
CY2023Q3 us-gaap Interest Expense
InterestExpense
1432000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1131000
us-gaap Interest Expense
InterestExpense
4057000
us-gaap Interest Expense
InterestExpense
3243000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1886000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
766000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5465000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
846000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12957000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22210000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44756000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-69298000

Files In Submission

Name View Source Status
sght-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
sght-20230930_cal.xml Edgar Link unprocessable
0000950170-23-060303-index-headers.html Edgar Link pending
0000950170-23-060303-index.html Edgar Link pending
0000950170-23-060303.txt Edgar Link pending
0000950170-23-060303-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sght-20230930.htm Edgar Link pending
sght-20230930.xsd Edgar Link pending
sght-ex10_2.htm Edgar Link pending
sght-ex10_3.htm Edgar Link pending
sght-ex31_1.htm Edgar Link pending
sght-ex31_2.htm Edgar Link pending
sght-ex32_1.htm Edgar Link pending
sght-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
sght-20230930_def.xml Edgar Link unprocessable
sght-20230930_lab.xml Edgar Link unprocessable
sght-20230930_htm.xml Edgar Link completed